Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas

被引:30
作者
Baron, Beverly W. [1 ]
Zeleznik-Le, Nancy
Baron, Miriam J.
Theisler, Catherine
Huo, Dezheng
Krasowski, Matthew D.
Thirman, Michael J.
Baron, Rebecca M.
Baron, Joseph M.
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[4] Loyola Univ, Ctr Med, Cardial Bernardin Canc Ctr, Maywood, IL 60153 USA
[5] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Cambridge, MA 02138 USA
关键词
human lymphomas; target of BCL6;
D O I
10.1073/pnas.0701770104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The human BCL6 gene on chromosome 3 band q27, which encodes a transcriptional repressor, is implicated in the pathogenesis of human lymphomas, especially the diffuse large B-cell type. We previously identified the human PDCD2 (programmed cell death-2) gene as a target of BCL6 repression. PDCD2 encodes a protein that is expressed in many human tissues, including lymphocytes, and is known to interact with corepressor complexes. We now show that BCL6 can bind directly to the PDCD2 promoter, repressing its transcription. Knockdown of endogenous BCL6 in a human B cell lymphoma line by introduction of small interfering RNA duplexes increases PDCD2 protein expression. Furthermore, there is an inverse relationship between the expression levels of the BCL6 and PDCD2 proteins in the lymphoid tissues of mice overexpressing human BCL6 (high BCL6 levels, minimal PDCD2) and controls (minimal BCL6, high PDCD2) as well as in tissues examined from some human B and T cell lymphomas. These data confirm PDCD2 as a target of BCL6 and support the concept that repression of PDCD2 by BCL6 is likely important in the pathogenesis of certain human lymphomas.
引用
收藏
页码:7449 / 7454
页数:6
相关论文
共 38 条
[21]   PROGRAMMED CELL-DEATH IN DEVELOPING GRAFTS OF FETAL SUBSTANTIA-NIGRA [J].
MAHALIK, TJ ;
HAHN, WE ;
CLAYTON, GH ;
OWENS, GP .
EXPERIMENTAL NEUROLOGY, 1994, 129 (01) :27-36
[22]   6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas [J].
Merup, M ;
Moreno, TC ;
Heyman, M ;
Rönnberg, K ;
Grandér, D ;
Detlofsson, R ;
Rasool, O ;
Liu, Y ;
Söderhäll, S ;
Juliusson, G ;
Gahrton, G ;
Einhorn, S .
BLOOD, 1998, 91 (09) :3397-3400
[23]   Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-Cell proto-oncogene product [J].
Nakamura, T ;
Yamazaki, Y ;
Saiki, Y ;
Moriyama, M ;
Largaespada, DA ;
Jenkins, NA ;
Copeland, NG .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (09) :3178-3186
[24]   IDENTIFICATION OF MESSENGER-RNAS ASSOCIATED WITH PROGRAMMED CELL-DEATH IN IMMATURE THYMOCYTES [J].
OWENS, GP ;
HAHN, WE ;
COHEN, JJ .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (08) :4177-4188
[25]   Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma [J].
Pasqualucci, L ;
Migliazza, A ;
Basso, K ;
Houldsworth, J ;
Chaganti, RSK ;
Dalla-Favera, R .
BLOOD, 2003, 101 (08) :2914-2923
[26]   The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells [J].
Phan, RT ;
Dalla-Favera, R .
NATURE, 2004, 432 (7017) :635-639
[27]   BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells [J].
Phan, RT ;
Saito, M ;
Basso, K ;
Niu, HF ;
Dalla-Favera, R .
NATURE IMMUNOLOGY, 2005, 6 (10) :1054-1060
[28]   Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells [J].
Polo, JM ;
Dell'Oso, T ;
Ranuncolo, SM ;
Cerchietti, L ;
Beck, D ;
Da Silva, GF ;
Prive, GG ;
Licht, JD ;
Melnick, A .
NATURE MEDICINE, 2004, 10 (12) :1329-1335
[29]   Genomic organisation and expression of BCL6 in murine B-cell lymphomas [J].
Qi, CF ;
Hori, M ;
Coleman, AE ;
Torrey, TA ;
Taddesse-Heath, L ;
Ye, BH ;
Chattopadhyay, SK ;
Hartley, JW ;
Morse, HC .
LEUKEMIA RESEARCH, 2000, 24 (08) :719-732
[30]   PDCD2 is a negative regulator of HCF-1 (C1) [J].
Scarr, RB ;
Sharp, PA .
ONCOGENE, 2002, 21 (34) :5245-5254